dc.contributor.author | Jain, R. K. | en |
dc.contributor.author | Martin, J. D. | en |
dc.contributor.author | Stylianopoulos, T. | en |
dc.creator | Jain, R. K. | en |
dc.creator | Martin, J. D. | en |
dc.creator | Stylianopoulos, T. | en |
dc.date.accessioned | 2019-05-06T12:23:45Z | |
dc.date.available | 2019-05-06T12:23:45Z | |
dc.date.issued | 2014 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/48436 | |
dc.description.abstract | Tumors generate physical forces during growth and progression. These physical forces are able to compress blood and lymphatic vessels, reducing perfusion rates and creating hypoxia. When exerted directly on cancer cells, they can increase cells' invasive and metastatic potential. Tumor vessels- while nourishing the tumor-are usually leaky and tortuous, which further decreases perfusion.Hypoperfusion and hypoxia contribute to immune evasion, promote malignant progression and metastasis, and reduce the efficacy of a number of therapies, including radiation. In parallel, vessel leakiness together with vessel compression causes a uniformly elevated interstitial fluid pressure that hinders delivery of blood-borne therapeutic agents, lowering the efficacy of chemo- and nanotherapies. In addition, shear stresses exerted by flowing blood and interstitial fluid modulate the behavior of cancer and a variety of host cells. Taming these physical forces can improve therapeutic outcomes in many cancers. Copyright © 2014 by Annual Reviews. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Annual Review of Biomedical Engineering | en |
dc.subject | Models | en |
dc.subject | theoretical model | en |
dc.subject | Theoretical | en |
dc.subject | human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Disease Progression | en |
dc.subject | review | en |
dc.subject | metastasis | en |
dc.subject | Neoplasm Metastasis | en |
dc.subject | tumor microenvironment | en |
dc.subject | disease course | en |
dc.subject | rectum cancer | en |
dc.subject | nonhuman | en |
dc.subject | pathology | en |
dc.subject | Stress | en |
dc.subject | tumor growth | en |
dc.subject | tumor vascularization | en |
dc.subject | bevacizumab | en |
dc.subject | drug mechanism | en |
dc.subject | pancreas cancer | en |
dc.subject | pathophysiology | en |
dc.subject | Animals | en |
dc.subject | animal | en |
dc.subject | immune system | en |
dc.subject | cancer resistance | en |
dc.subject | cell invasion | en |
dc.subject | hypoxia | en |
dc.subject | treatment failure | en |
dc.subject | chemistry | en |
dc.subject | Vascular Endothelial Growth Factor A | en |
dc.subject | vasculotropin A | en |
dc.subject | metastasis potential | en |
dc.subject | Blood | en |
dc.subject | drug delivery system | en |
dc.subject | Drug Delivery Systems | en |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | glioblastoma | en |
dc.subject | Tumors | en |
dc.subject | Diseases | en |
dc.subject | extracellular fluid | en |
dc.subject | tissue pressure | en |
dc.subject | perfusion | en |
dc.subject | losartan | en |
dc.subject | Mechanical | en |
dc.subject | Blood vessels | en |
dc.subject | monoclonal antibody DC101 | en |
dc.subject | angiogenesis inhibitor | en |
dc.subject | tumor blood flow | en |
dc.subject | blood vessel permeability | en |
dc.subject | mechanical stress | en |
dc.subject | stress alleviation | en |
dc.subject | tumor perfusion | en |
dc.subject | vascular normalization | en |
dc.subject | angiotensin receptor antagonist | en |
dc.subject | anoxia | en |
dc.subject | blood vessel occlusion | en |
dc.subject | cediranib | en |
dc.subject | Enzyme inhibition | en |
dc.subject | force | en |
dc.subject | immune evasion | en |
dc.subject | lymph | en |
dc.subject | lymphatic system | en |
dc.subject | microcirculation | en |
dc.subject | saridegib | en |
dc.subject | shear strength | en |
dc.subject | shear stress | en |
dc.subject | solid stress | en |
dc.subject | tissue perfusion | en |
dc.subject | vascular hyperpermeability | en |
dc.subject | vasculotropin inhibitor | en |
dc.subject | vessel compression | en |
dc.title | The role of mechanical forces in tumor growth and therapy | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1146/annurev-bioeng-071813-105259 | |
dc.description.volume | 16 | |
dc.description.startingpage | 321 | |
dc.description.endingpage | 346 | |
dc.author.faculty | Πολυτεχνική Σχολή / Faculty of Engineering | |
dc.author.department | Τμήμα Μηχανικών Μηχανολογίας και Κατασκευαστικής / Department of Mechanical and Manufacturing Engineering | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Stylianopoulos, T. [0000-0002-3093-1696] | |
dc.description.totalnumpages | 321-346 | |
dc.gnosis.orcid | 0000-0002-3093-1696 | |